Edwards Lifesciences' Stock Outperforms Peers with 15.2% YTD Gain

Edwards Lifesciences Corporation (EW) has a market cap of $50.3 billion and provides products and technologies for treating advanced cardiovascular diseases. The stock has gained 4.8% over the past three months and outperformed the iShares U.S. Medical Devices ETF (IHI) during the same time frame. EW stock has soared 15.2% YTD and 19.5% over the past 52 weeks. The consensus rating is a "Moderate Buy" with a mean price target of $93.68, suggesting a 9.9% upside potential from current price levels.